Yanshengchao successfully completed a Pre-Series A financing round, led by Qiming Venture Partners, to support the development of innovative therapies for autoimmune diseases.
Target Information
Recently, Yanshengchao (Beijing) Biotechnology Co., Ltd. (hereinafter referred to as "Yanshengchao") successfully secured hundreds of millions of RMB in a Pre-Series A financing round, led by Qiming Venture Partners. The funds raised will primarily support the clinical development of the core pipeline YSC001 and the preclinical development of YSC002, as well as accelerate the company's international strategy and business development collaborations with multinational pharmaceutical companies.
Founded in 2022, Yanshengchao is based on original research conducted by the team at Tsinghua University's School of Medicine in the field of fluid immunity. The company focuses on developing new drugs for inflammatory and autoimmune diseases targeting globally innovative (FIC, First-in-Class) mechanisms, addressing core challenges and highly unmet clinical needs in the field.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in China
China's biotechnology industry has seen rapid growth over the past few years, driven by significant investments and a supportive regulatory environment. The country is becoming a global hub for biotech innovations
Similar Deals
Qiming Venture Partners → Iongen Therapeutics Co., Ltd.
2025
启明创投
invested in
演生潮（北京）生物科技有限公司
in 2025
in a Pre-Seed Stage deal